NASDAQ:ALGS Aligos Therapeutics Q3 2025 Earnings Report $10.04 +0.11 (+1.06%) Closing price 03:59 PM EasternExtended Trading$10.16 +0.13 (+1.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aligos Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$2.09Beat/MissN/AOne Year Ago EPSN/AAligos Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.50 millionBeat/MissN/AYoY Revenue GrowthN/AAligos Therapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Aligos Therapeutics Earnings HeadlinesAligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025October 7 at 10:25 AM | markets.businessinsider.comAligos Therapeutics, Inc. Announces Eight Presentations at The Liver Meeting® 2025, Including Oral Presentation on Novel HBV TherapyOctober 7 at 8:51 AM | quiverquant.comQYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.October 9 at 2:00 AM | Priority Gold (Ad)Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025October 7 at 8:30 AM | globenewswire.comAligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV MeetingSeptember 3, 2025 | globenewswire.comAligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections. Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners. The company’s lead program for chronic hepatitis B (CHB) employs a combination approach to silence viral genes and stimulate immune clearance. In parallel, Aligos is progressing antiviral candidates for respiratory viruses, including coronaviruses and influenza, by targeting key viral enzymes and immune pathways. Aligos’s clinical development strategy emphasizes combination regimens that may offer functional cures rather than life‐long treatment. Its respiratory virus portfolio includes direct‐acting antivirals targeting viral polymerases, alongside immune modulators intended to enhance host defense mechanisms. By integrating novel chemistries with established antiviral targets, the company aims to deliver differentiated therapies across multiple indications. With clinical trials conducted in North America and partnerships extending to global research centers, Aligos is focused on generating robust data to support regulatory filings. The management team brings deep experience in antiviral drug development, clinical operations and regulatory strategy, positioning the company to advance its mission of developing innovative solutions for patients living with chronic and acute viral diseases.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
